Immune cell therapy takes on tough scleroderma

NCT ID NCT07493395

Recruiting now Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early trial tests whether a single infusion of anti-CD19 CAR T-cells can improve skin thickening and other symptoms in 6 adults with severe, treatment-resistant systemic sclerosis. Participants receive chemotherapy before the infusion and are monitored for 24 months. The study focuses on safety and how the cells behave in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anti-CD19 CAR T-cells (a type of immune cell therapy)
What this could lead to: If it works, this could point toward a new treatment option for people with severe scleroderma that hasn't responded to other drugs.
What could go wrong: This is a very early, small trial with only 6 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCLERODERMA, SYSTEMIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCLERODERMA, SYSTEMIC

Contacts and locations

Locations

APHP Necker
NOT_YET_RECRUITING

Paris, France
CHRU Lille
NOT_YET_RECRUITING

Lille, France
Chu Rouen
NOT_YET_RECRUITING

Rouen, France
Montpellier University Hospital
RECRUITING

Montpellier, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.